24/7 Market News Snapshot 26 February, 2025 – Pyxis Oncology, Inc. Common Stock (NASDAQ:PYXS)

February 26, 2025

DENVER, Colo., 26 February, 2025 (247marketnews.com) – (NASDAQ:PYXS) are discussed in this article.
Pyxis Oncology, Inc. (PYXS) is experiencing significant momentum, with its shares trading at $1.315 in pre-market, representing a notable 9.58% increase from the previous close of $1.200. Accompanied by strong trading volume of 1.24 million shares, this surge signals heightened investor interest and potential for continued upward movement, reinforcing the outlook for short-term gains as traders analyze key resistance levels.

In conjunction with this positive market trend, Pyxis has also made a breakthrough in cancer treatment, as the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its candidate, PYX-201. This innovative therapy targets adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who have not responded to existing treatment options.

PYX-201 represents a first-in-class antibody-drug conjugate (ADC) specifically designed to target Extradomain-B Fibronectin (EDB+FN), a structural component commonly found in the tumor extracellular matrix. This targeted approach is critical for addressing the significant unmet medical needs within this patient population, which demonstrates an alarming increase in incidence rates.

Dr. Lara S. Sullivan, President and Chief Executive Officer of Pyxis Oncology, expressed her optimism regarding the FDA designation, highlighting it as a milestone in their mission to expedite the development of effective therapies for challenging diseases. The Fast Track program enables greater interaction with the FDA, potentially streamlining the drug’s path to market.

As Pyxis Oncology progresses in its clinical trials, including studies assessing PYX-201 in combination with Merck’s KEYTRUDA®, the company is committed to advancing innovative solutions for hard-to-treat cancers, ultimately enhancing patient care and treatment efficacy within the oncology field.

Related news for (PYXS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.